Safety and efficacy of fresh whole blood donor lymphocyte infusion in children.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
27
12
2018
accepted:
12
05
2019
revised:
18
04
2019
pubmed:
1
6
2019
medline:
18
9
2020
entrez:
1
6
2019
Statut:
ppublish
Résumé
Donor lymphocyte infusion (DLI) is a form of cellular immunotherapy which is known to be effective in preventing relapse in leukemia by inducing graft versus leukemia (GVL) effect. In hematopoietic stem cell transplantation (HSCT) for benign hematological conditions including primary immune deficiency, mixed chimerism is seen with the use of reduced intensity conditioning. DLI can help prevent graft rejection by boosting the existing graft in these situations. There is scant data on the use of DLI in children who have undergone HSCT for benign hematological disorders. We present our case series with early withdrawal of immunosuppression and DLI as a means to mitigate relapse of leukemia and prevent graft rejection in mixed chimerism in children transplanted for benign hematological disorders. Donor lymphocyte infusion was given in a graded regimen with the cell dose of 1 × 10
Identifiants
pubmed: 31148600
doi: 10.1038/s41409-019-0580-7
pii: 10.1038/s41409-019-0580-7
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1892-1897Références
Marsh RA, Vaughn G, Kim MO, Dandan Li, Jodele S, Joshi S, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116:5824–31.
doi: 10.1182/blood-2010-04-282392
Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 2003;31:229–39.
doi: 10.1038/sj.bmt.1703839
Cooper N, Rao K, Gilmour K, Hadad L, Adams S, Cale C, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood. 2006;107:1233–6.
doi: 10.1182/blood-2005-05-1819
Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–5.
doi: 10.1182/blood.V76.12.2462.2462
Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood. 1995;86:2041–50.
doi: 10.1182/blood.V86.5.2041.bloodjournal8652041
Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–44.
doi: 10.1200/JCO.1997.15.2.433
Kolb HJ, Mittermuller J, Holler E, Thalmeier K, Bartram CR. Graft-versus-host reaction spares normal stem cells in chronic myelogenous leukemia. Bone Marrow Transplant. 1996;17:449–52.
pubmed: 8704705
Castagna L, Sarina B, Bramanti S, Perseghin P, Mariotti J, Morabito L. Donor lymphocyte infusion after allogeneic stem cell transplantation. Transfus Apher Sci. 2016;54:345–55.
doi: 10.1016/j.transci.2016.05.011
Mark DI et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100:3108–114.
doi: 10.1182/blood-2002-02-0506
Rujkijyanont P, Morris C, Kang G, Gan K, Hartford C, Triplett B, et al. Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia. Blood Cancer J. 2013;3:e137.
doi: 10.1038/bcj.2013.39
Haines L, Bleesing J, Davies S, Hornung L, Jordan M, Marsh RA, et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transpl. 2015;21:288e292.
doi: 10.1016/j.bbmt.2014.10.010
Abraham A, Hsieh M, Eapen M, Fitzhugh C, Carreras J, Keesler D, et al. Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2017;23:2178–83.
doi: 10.1016/j.bbmt.2017.08.038
Fitzhugh CD, Walters MC. The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia. Blood Adv. 2017;1:2563–7.
doi: 10.1182/bloodadvances.2017007708
George B, Viswabandya A, Abraham A, Sindhuvi E, Ganapule A, Fouzia NA, et al. Increased incidence of mixed chimerism with the use of fludarabine-treosulfan based conditioning in patients undergoing allogeneic stem cell transplantation for thalassaemia major. Biol Blood Marrow Transpl. 2015;21:284–5.
doi: 10.1016/j.bbmt.2014.11.451
Luznik L et al. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control. 2002;9:123–37.
doi: 10.1177/107327480200900205